BioCentury | Nov 26, 2020
Product Development

U.S. government spending on Abbott BinaxNOW outstrips other rapid COVID-19 tests: Data Byte

Abbott’s BinaxNOW test has replaced its predecessor as the Trump Administration’s favorite COVID-19 test. A fact sheet released by HHS Tuesday showed the U.S. federal government has spent $760 million on the antigen test from Abbott...
BioCentury | Nov 25, 2020
Product Development

Russia to launch Sputnik V vaccine into global orbit

The Russian government plans to exploit the low manufacturing cost and ease of storing and transporting its Sputnik V vaccine to engage in vaccine diplomacy, filling a gap left by the Trump administration’s America First...
BioCentury | Nov 25, 2020
Regulation

With Oxlumo’s approval, Alnylam aims to speed access with new value-based pricing framework

With the approval of Oxlumo to treat primary hyperoxaluria, Alnylam is aiming to accelerate patient access to the ultra-rare disease therapy by building on the performance- and prevalence-based pricing...
BioCentury | Nov 21, 2020
Product Development

How Forma is working to show the sickle cell community it’s in for the long haul

As early clinical evidence for its sickle cell disease candidate grows, Forma is prioritizing building relationships with the patient community, with a focus on long-term policy goals and COVID-19 safety...
BioCentury | Nov 20, 2020
Finance

SR One’s newfound freedom allows firm to increase focus on company creation

SR One’s spinout from GSK gives the newly independent VC the ability to scale up what has been a top-tier investment firm over the past decade, along with the freedom to take larger stakes...
BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

BrainStorm sees path forward for ALS therapy despite Phase III missBrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) shed $7.92 (66%) to $4.02 on Tuesday after its mesenchymal stem cell therapy NurOwn missed the primary endpoint in a...
BioCentury | Nov 14, 2020
Product Development

Complete response for Sanofi’s rare anemia candidate; plus Sumitovant-Urovant, C4-Roche, IN8bio and Synendos

Setback for Sanofi rare anemia therapySanofi (Euronext:SAN; NASDAQ:SNY) said late Friday that FDA issued a complete response letter to a BLA for anti-C1s mAb sutimlimab to treat hemolysis in adults with cold agglutinin disease, a rare anemia....
BioCentury | Nov 14, 2020
Politics, Policy & Law

U.K.’s opportunity as changes come to MHRA, NICE

On the cusp of a new era outside of Europe, the U.K. has an opportunity to create an innovative and interconnected regulatory and reimbursement system that can attract biopharma by accelerating patient...
BioCentury | Nov 14, 2020
Deals

Innovation in a hurry: China biotechs see a fast track to global stage – survey

The Chinese biopharma landscape in five years will see a majority of the money magnet companies commanding innovation, with first-in-class targets filling their pipelines and innovative biologics outpacing...
BioCentury | Nov 12, 2020
Product Development

Russian vaccine data add to expectations for COVID-19 vaccine efficacy set by BioNTech, Pfizer; Moderna readout coming

The first interim Phase III readout for Sputnik V suggests the Russian COVID-19 vaccine and BNT162b2 from BioNTech and Pfizer have similar efficacies as an interim analysis that will reveal whether Moderna...
Items per page:
1 - 10 of 12186